CAS 649735-63-7 appears in our catalog under these names: Brivanib Alaninate, Brivanib Alaninate (BMS–582664), Brivanib (alaninate)/ 99.23% (existing batch purity), Brivanib alaninate, 95.00%, Brivanib (alaninate) 98%. Offered by: TRC, GLPBio, TargetMol, Biosynth, Chemat. Available pack sizes: 10mg, 50mg, 5mg, 100mg, 25mg, 10mM (in 1ml dmso), 1mg, 2mg.
Brivanib alaninate is a carboxylic ester resulting from the formal condensation of the carboxy group of L-alanine with the hydroxy group of brivanib. It is a prodrug of brivanib (BMS-540215), a potent oral dual inhibitor of VEGFR-2 and FGFR-1 (IC50 of 25 nM and 148 nM, respectively) and was in development for the treatment of hepatocellular and colon carcinomas. It has a role as an antineoplastic agent, an angiogenesis inhibitor, a prodrug, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a fibroblast growth factor receptor antagonist and an apoptosis inducer. It is a fluoroindole, a carboxylic ester, an aromatic ether, a diether, a L-alanine derivative and a pyrrolotriazine. It is functionally related to a brivanib.
Source: ChEBI
| Molecular formula | C22H24FN5O4 |
|---|---|
| Molecular weight | 441.5 g/mol |
| IUPAC name | [(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-yl] (2S)-2-aminopropanoate |
| InChIKey | LTEJRLHKIYCEOX-OCCSQVGLSA-N |
| SMILES | CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)OC(=O)[C@H](C)N)C |
Computed by PubChem (NCBI)